Protollin is a drug initially formulated as a vaccine adjuvant. [1] [2] It is composed of lipopolysaccharides derived from the Shigella flexneri or Pleisiomonas shigelloides bacterium combined with hydrophobic outer membrane proteins derived from Neisseria meningitidis. [3] [4]
On November 16, 2021, Brigham and Women's Hospital announced that it was beginning a Phase I clinical trial of Protollin as a nasally-delivered vaccine to activate the body's immune response against amyloid proteins that form in the brain and are thought to contribute to the symptoms of Alzheimer's disease. [5] [6]
Protollin is a drug initially formulated as a vaccine adjuvant. [1] [2] It is composed of lipopolysaccharides derived from the Shigella flexneri or Pleisiomonas shigelloides bacterium combined with hydrophobic outer membrane proteins derived from Neisseria meningitidis. [3] [4]
On November 16, 2021, Brigham and Women's Hospital announced that it was beginning a Phase I clinical trial of Protollin as a nasally-delivered vaccine to activate the body's immune response against amyloid proteins that form in the brain and are thought to contribute to the symptoms of Alzheimer's disease. [5] [6]